AVEO Oncology to Present at the Jefferies 2018 Healthcare Conference
May 31 2018 - 7:00AM
Business Wire
AVEO Oncology (NASDAQ: AVEO) today announced that Michael
Bailey, president and chief executive officer, will present at the
Jefferies 2018 Healthcare Conference in New York on Thursday, June
7, 2018 at 9:30 a.m. Eastern Time.
A live webcast of the presentation can be accessed by visiting
the investors section of the Company’s website
at www.aveooncology.com. A replay of the webcast will be
archived for 30 days following the presentation date.
About AVEO
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted therapeutics for oncology
and other areas of unmet medical need. The Company is focused on
seeking to develop and commercialize its lead candidate tivozanib,
a potent, selective, long half-life inhibitor of vascular
endothelial growth factor 1, 2 and 3 receptors, in North America as
a treatment for renal cell carcinoma and other cancers. AVEO is
leveraging multiple partnerships aimed at developing and
commercializing tivozanib in oncology indications outside of North
America, and at progressing its pipeline of novel therapeutic
candidates in cancer and other areas of unmet medical need.
Tivozanib (FOTIVDA®) is approved by the European Commission for the
treatment of adult patients with advanced renal cell carcinoma in
the European Union plus Norway and Iceland. For more information,
please visit the Company’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements
of AVEO that involve substantial risks and uncertainties.
All statements, other than statements of historical fact, contained
in this press release are forward-looking statements. Actual
results or events could differ materially due to a number of
important factors, including risks discussed in the section titled
“Risk Factors” in AVEO’s most recent Annual Report on Form 10-K,
its quarterly reports on Form 10-Q and its other filings with
the SEC. The forward-looking statements in this press release
represent AVEO’s views as of the date of this press
release. AVEO anticipates that subsequent events and
developments may cause its views to change.
While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180531005107/en/
AVEO:Argot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2023 to Apr 2024